GE HealthCare Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments at the Point of Care at ESC 2024

Rhea-AI Summary

GE HealthCare (Nasdaq: GEHC) announced CE marks for two innovative cardiology solutions: the Vscan Air™ SL with Caption AI™, an AI-driven handheld ultrasound system for rapid cardiac assessments, and ECG-less Cardiac CT scanning on its Revolution Apex™ platform. These technologies aim to enable more efficient and timely cardiac care at the point of service.

The Vscan Air SL with Caption AI provides real-time guidance for capturing cardiac images, even for non-experts, and includes an AutoEF feature for calculating left ventricular ejection fraction. The ECG-less Cardiac CT solution allows for cardiac imaging without an ECG signal, prioritizing patient access and speed.

Both innovations will be showcased at the European Society of Cardiology (ESC) Congress in London, August 30-September 2, 2024, along with GE HealthCare's Allia™ IGS 5 Pulse image-guided platform for interventional cardiology.

Positive

• CE mark approval for Vscan Air SL with Caption AI and ECG-less Cardiac CT scanning
• AI-driven technology enabling non-experts to capture diagnostic-quality cardiac images
• ECG-less Cardiac CT scanning enhances patient access and speed of cardiac imaging
• Showcase of innovative cardiology solutions at ESC Congress 2024

Negative

• None.

Insights

Medical Research Analyst

The CE marking of GE HealthCare's Vscan Air™ SL with Caption AI and ECG-less Cardiac CT scanning represents a significant advancement in cardiac imaging technology. These innovations address critical needs in cardiovascular care:

• Vscan Air SL with Caption AI enables non-experts to capture diagnostic-quality cardiac images, potentially expanding early detection capabilities in primary care and emergency settings.
• ECG-less Cardiac CT allows for faster and more accessible cardiac imaging, particularly beneficial when ECG signals are unavailable or time is critical.

These technologies could lead to earlier diagnosis and more efficient treatment of cardiovascular diseases, potentially improving patient outcomes in a field where timely intervention is crucial. However, the real-world impact on diagnostic accuracy and patient care will need to be closely monitored as these technologies are adopted more widely.

Financial Analyst

While the CE marking of these cardiac imaging technologies is a positive development for GE HealthCare, the immediate financial impact may be . Key considerations include:

• The addressable market for these technologies could be substantial, given the global prevalence of cardiovascular diseases.
• However, adoption rates may be gradual, dependent on factors such as healthcare budgets, training requirements and integration with existing systems.
• The competitive landscape in medical imaging is intense and GE HealthCare will need to demonstrate clear clinical and economic benefits to drive sales.

Investors should monitor sales figures and market share data in upcoming quarters to gauge the commercial success of these innovations. Long-term, these products could strengthen GE HealthCare's position in the cardiology market, but near-term financial impact may be modest.

Tech Expert

The integration of AI in GE HealthCare's new cardiac imaging solutions represents a significant technological leap in medical diagnostics:

• Caption AI's ability to guide non-experts in capturing cardiac images could democratize access to high-quality cardiac diagnostics, potentially revolutionizing primary care and emergency medicine.
• The ECG-less Cardiac CT technology demonstrates advanced signal processing capabilities, overcoming traditional limitations in cardiac imaging.
• The Effortless Workflow feature, with its 56% reduction in positioning time and 21% reduction in total exam time, showcases the potential of AI to significantly enhance operational efficiency in healthcare settings.

These innovations align with broader trends in healthcare AI, focusing on improving accessibility, efficiency and diagnostic accuracy. However, the long-term success of these technologies will depend on their real-world performance, user acceptance and ability to integrate seamlessly into existing healthcare workflows.

• CE mark of these next-generation cardiac imaging systems will further enable connected care along the cardiology patient journey and provide clinicians with the tools to deliver more efficient and timely care

CHICAGO--(BUSINESS WIRE)-- Today, GE HealthCare (Nasdaq: GEHC) announced the CE marks of its Vscan Air™ SL wireless handheld ultrasound system with Caption AI™ (Vscan Air SL with Caption AI), an artificial intelligence (AI)-driven software for rapid cardiac assessments at the point of care, as well as ECG-less Cardiac computed tomography (CT) scanning on its Revolution Apex™ platform, which allows clinicians to acquire cardiac images without the aid of the patients’ electrocardiogram (ECG) signal/trace. Both technologies will be showcased at the European Society of Cardiology (ESC) Congress, in London, August 30-September 2, 2024.

Cardiovascular diseases are the leading cause of death globally, claiming an estimated 17.9 million lives each year. There is an urgent need to diagnose cardiovascular disease earlier to help curb cardiac deaths across the world as more than 60% of these deaths are preventable and premature.^1,2 In order to meet this challenge, clinicians across various care areas need the best possible tools and technologies to diagnose and treat cardiovascular disease more efficiently to enable better patient outcomes.

GE HealthCare will showcase its latest technology that brings high-quality imaging to the patient’s bedside, cardiac catheterization laboratory and other hospital settings. The ultraportable Vscan Air SL with Caption AI is designed to help more healthcare professionals capture cardiac images so that even non-experts in cardiac ultrasound can help tell the story of their patients’ hearts, better informing diagnoses and treatment plans. Access to this novel technology enables earlier heart disease detection and expands cardiac care into primary care and emergency settings. Vscan Air SL with Caption AI can provide real-time, step-by-step visual guidance to optimize probe movements and includes a quality meter to ensure the user obtains the best possible images. Once a user captures an image, the AutoEF (ejection fraction) feature automatically calculates a left ventricular ejection fraction (LVEF), an important measure of heart function.

During the ESC Congress, three dedicated educational tutorials will be held on-site for Vscan Air SL with Caption AI, including live scanning demonstrations. Find out more here.

“With diseases of the heart and blood vessels representing nearly one-third of all global deaths, innovation within cardiac diagnostics and treatment is one of our top priorities as a healthcare company,” said Phil Rackliffe, president and CEO of Ultrasound and Image Guided Therapies, GE HealthCare. “The integration of Caption AI on Vscan Air SL is a major step toward helping more users confidently capture diagnostic-quality images to inform clinical decisions when time is of the essence. With the recent CE mark, we’re eager to bring this technology to more healthcare providers around the world.”

GE HealthCare will also be showcasing the recently CE marked and U.S. FDA cleared ECG-less Cardiac CT solution, which can acquire cardiac images without the aid of the patients’ ECG signal/trace. This technology is applied in examinations where it is clinically advantageous to prioritize patient access or speed when the ECG signal is unavailable. ECG-less Cardiac CT scanning is exclusively available on and further enhances the capabilities of the company’s Revolution Apex Elite, which already boasts a 160mm detector configuration and the ability to achieve one-beat, high definition, motion-free coronary images at any heart rate. This system is available as a part of GE HealthCare’s broader Revolution Apex platform, a world class scalable CT solution that offers modern computed tomography (CT) technology to provide versatile clinical solutions for even the most challenging patients.

The advanced technology is further enhanced with Effortless Workflow, which intelligently automates the CT workflow from pre-scan protocoling to post-scan processing, using AI-based features to help transform the entire CT experience and provide optimal efficiency, accuracy, clarity and consistency. This enables technologists to personalize scans automatically and accurately for each patient with significantly less effort. The results are high quality CT images acquired more quickly and efficiently: 56% reduction in positioning time³; 66% reduction in total exam clicks⁴; and 21% reduction in total exam time⁵.

“Providing rapid, flexible and at the point of care cardiac diagnostics is critical in terms of patient outcomes – however, timely care can be extremely difficult to deliver, particularly within already-stretched healthcare systems where clinicians face time and resource constraints,” said Eigil Samset, general manager, Cardiology Solutions, GE HealthCare. “Through our innovative cardiology solutions and by leveraging the power of AI, we aim to address these challenges and help clinicians understand the complete story of their patients’ hearts as quickly as possible. I am thrilled that this suite of integrated cardiac care solutions is now accessible to more providers so that they are able to deliver efficient and timely patient care when and where it is needed most.”

Building on the recent CE marks, these innovative cardiology solutions will be on display at GE HealthCare Booth # F400 South in a fully functional cardiac catheterization laboratory at ESC Congress 2024. The lab will showcase the company’s latest image guided platform Allia™ IGS 5 Pulse, designed to improve workflow for the diagnosis and treatment of cardiovascular diseases in interventional cardiology, as well as feature INTERACT Touch with AVVIGO+™ Multi-Modality Guidance System from Boston Scientific⁶ - the first third party application available with this technology.

To learn more about the GE HealthCare solutions that will be showcased on-site at ESC Congress 2024 or to register for one of the 33 tutorial sessions and live demonstrations sponsored by the company, please visit https://events.gehealthcare.com/events/esc-2024/.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction, and GE HealthCare Technologies Inc.’s (the “Company’s”) performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

____________________

1 World Health Organization. Cardiovascular diseases (CVDs). June 11, 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed July 2024.

2 Vaduganathan M, Mensah G, Turco J, et al. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. JACC. 2022;80(25):2361-2371. https://doi.org/10.1016/j.jacc.2022.11.005

3 The data was based on comparison between GE HealthCare’s legacy products (16 ch and 64 ch scanner) and Revolution Ascend in the three institutions using a pilot product and selected routine head and body. The data set of this comparison was 838 exams for legacy products and 1387 exams for Revolution Ascend. The time saving value may not be effective for all institutions depending on the clinical practice. Defined the scan setting time is from “Open new patient” to “Confirm setting for Scout”

4 The required clicks are defined as clicks required to execute a scan from selecting a new patient till start scan. All associated clicks for and in clinical practice, number of the required clicks may vary depending on the circumstances, including but not limited to, the clinical task, exam type, clinical practice, and image reconstruction technique.

5 The data was based on comparison between GE HealthCare’s legacy products (16 ch and 64 ch scanner) and Revolution Ascend in the three institutions using a pilot product and selected routine head and body. The data set of this comparison was 838 exams for legacy products and 1387 exams for Revolution Ascend. The time saving value may not be effective for all institutions depending on the clinical practice. Definition of entire exam time is from “Open new patient” to “Last primary recon completed” for Revolution Ascend and “Close exam” for legacy products.

6 INTERACT Touch with AVVIGO+ is pending CE Mark and not available for sale.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826680336/en/

GE HealthCare Media Contact

Karin Dalsin

Global Communications Director

karin.dalsin@gehealthcare.com

+1-612-219-2855

Source: GE HealthCare

FAQ

What new cardiology solutions did GE HealthCare (GEHC) receive CE marks for?

GE HealthCare received CE marks for the Vscan Air SL with Caption AI, an AI-driven handheld ultrasound system, and ECG-less Cardiac CT scanning on its Revolution Apex platform.

When and where will GE HealthCare (GEHC) showcase its new cardiology solutions?

GE HealthCare will showcase its new cardiology solutions at the European Society of Cardiology (ESC) Congress in London, from August 30 to September 2, 2024.

What is the main benefit of the Vscan Air SL with Caption AI system from GE HealthCare (GEHC)?

The main benefit of the Vscan Air SL with Caption AI is that it enables non-experts in cardiac ultrasound to capture diagnostic-quality cardiac images, expanding cardiac care into primary care and emergency settings.

How does the ECG-less Cardiac CT scanning from GE HealthCare (GEHC) improve patient care?

The ECG-less Cardiac CT scanning improves patient care by allowing cardiac imaging without an ECG signal, prioritizing patient access and speed in situations where the ECG signal is unavailable or when faster imaging is clinically advantageous.